Información del artículo
El carcinoma medular de tiroides (CMT) es un tumor tiroideo maligno primario secretor de calcitonina que puede presentarse de forma esporádica o familiar. Presentamos el caso de un paciente afectado de CMT esporádico con metástasis a distancia que expresa receptores para somatostatina y concentraciones séricas de calcitonina dentro de la normalidad. Se describe la clínica, la anatomía patológica, los factores pronósticos, el diagnóstico y el tratamiento con análogos de la somatostatina.
Palabras clave:
Carcinoma medular de tiroides
Calcitonina
Receptores de somatostatina
Análogos de somatostatina
Medullary thyroid carcinoma (MTC) is a primary malignant tumor secreting calcitonin, which can appear sporadically or as a familiar tumor. We present a case of a patient suffering from sporadic MTC with distant metastases that express somatostatin receptors and serum calcitonin within normal levels. We describe clinical, pathological anatomy, pronostic factors, diagnosis as well as the treatment with somatostatin analogues.
Key words:
Medullary thyroid carcinoma
Calcitonin
Somatostatin receptors
Somatostatin analogues
El Texto completo está disponible en PDF
Bibliografía
[1.]
D. Giuffrida, H. Gharib.
Current diagnosis and management of medullary thryroid carcinoma.
Ann Oncol, 9 (1998), pp. 695-701
[2.]
K.J. O'Byrne, N. O'Hare, E. Sweeney, P.J. Freyne, M.J. Cullen.
Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
Nucl Med Commun, 17 (1996), pp. 810-816
[3.]
Y. Krausz, A. Rosler, H. Guttmann, S. Ish-Shalom, N. Shibley, R. Chisin, et al.
Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.
Clin Nucl Med, 24 (1999), pp. 256-260
[4.]
A. Kurtaran, C. Scheuba, K. Kaserer, W. Schima, C. Czereny, P. Angelberger, et al.
Indium 111- DTPA-D-Phe-1 octreotide and Technetium-99m-(V)- dimercaptosuccinic acid scanning in the preoperative staging of medullary thryroid carcinoma.
J Nucl Med, 39 (1998), pp. 1907-1909
[5.]
W. Shi, C.F. Jhonston, K.D. Buchanan, W.R. Ferguson, J.D. Laird, J.G. Croters, et al.
Localization of neuroendocrine tumours with (111In) DTPAoctreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
QJM, 91 (1998), pp. 295-301
[6.]
T. Frick, F. Franebo, L. Grimelius, A. Hoog, G. Wallin, C. Larsson.
Expression of RET and its ligands complexes, GDNF/GFR alpha-1 and NTN/GFR alpha-2 in medullary thyroid carcinomas.
Eur J Endocrinol, 142 (2000), pp. 643-649
[7.]
C. Eng, G.A. Thomas, C.S. Neuberg, L.M. Mulligan, C.S. Healey, C. Hougton, et al.
Mutation of the RET proto-oncogene is correlated with RET inmunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma.
J Clin Endocrin Metab, 83 (1998), pp. 4310-4313
[8.]
K. Papaparaskeva, H. Nagel, M. Droese.
Cytologic diagnosis of medullary carcinoma of the thyroid gland.
Diagn Cytopathol, 22 (2000), pp. 351-358
[9.]
B. Kebebew, P.H. Ituarte, A.E. Siperstein, Q.Y. Duh, O.H. Clark.
Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors and a comparison of staging systems.
Cancer, 88 (2000), pp. 1139-1148
[10.]
E. Modigliani, R. Cohen, J.M. Campos, B. Conte-Devlox, B. Maes, A. Boneu, et al.
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine.
Clin Endocrinol (Oxf), 48 (1998), pp. 265-273
[11.]
A.H. Redding, S.N. Levine, M.R. Fowler.
Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses.
Thyroid, 10 (2000), pp. 919-922
[12.]
J. Rosai.
Ackerman's surgical pathology (Vol I). eighth edition Mosby-Yearbook Inc.
pp. 542
[13.]
L. Berna, A. Chico, X. Matías-Guiu, E. Mato, A. Catafau, C. Alonso, et al.
Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Eur J Nucl Med, 25 (1998), pp. 1482-1488
[14.]
G. Vitale, E. Cascone, G. Lupoli Jr, A. Ciccarelli, C. Barone, G. Lupoli.
New developments in the treatment of medullary thyroid carcinoma.
Minerva Endocrinol, 23 (1998), pp. 121-128
[15.]
G. Faglia, M. Arosio.
Therapeutic use of somatostatin analogues in endocrinology.
Recenti Prog Med, 83 (1992 Nov), pp. 626-633
[16.]
J.M. Guliana.
Role of non surgical therapeutics in the treatment of patients with medullary cancer of thyroid.
Ann Endocrinol (Paris), 57 (1996), pp. 33-40
[17.]
D.W. Zlock, F.S. Greenspan, O.H. Clark, C.B. Higgins.
Octreotide therapy in advanced thyroid cancer.
Thyroid, 4 (1994), pp. 427-431
[18.]
G. Lupoli, E. Cascone, F. Arlotta, G. Vitale, L. Celentano, M. Salvatore, et al.
Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide.
Cancer, 78 (1996), pp. 1114-1118
[19.]
G. Vitale, P. Tagliaferri, M. Caraglia, E. Rampone, A. Ciccarelli, A.R. Bianco, et al.
Slow release lanreotide in combination with interferon alpha-2b in the treatment of syntomatic advanced medullary thyroid carcinoma.
J Clin Endocrinol Metab, 85 (2000), pp. 983-988
Copyright © 2002. Sociedad Española de Endocrinología y Nutrición
